Key Highlights

  • Croda International Plc (LSE:CRDA) fell 1.20% to 3,622p on 9 November 2026, among the FTSE 100 fallers during a risk-on rally.
  • The speciality chemicals group has been working through a prolonged recovery after a de-stocking cycle.
  • Croda supplies ingredients to beauty, personal care, pharmaceutical, crop protection and industrial customers.
  • Higher energy costs linked to the Iran war affect input and production costs.
  • The FTSE 100 large-cap Value Stock is watched for Demand recovery, margins and cost savings.

Why Croda International Plc (LSE:CRDA) Is Trending

Croda International Plc (LSE:CRDA) has been on the wrong side of this week's market rotation. On Monday, 9 November, when investors bought miners, airlines and defence stocks, Croda was among the FTSE 100 fallers, down 1.20% to 3,622p. The Yorkshire-based speciality chemicals group has been trying to convince investors that its recovery is under way, but demand remains uneven.

The broader market saw strong gains, with the FTSE 100 closing the week at a three-month high on 13 November 2026. Speciality chemicals, however, have struggled to attract buyers because of weak industrial demand and cost pressures.

What Croda Makes

Croda produces high-value ingredients and technologies used in beauty and personal care products, pharmaceuticals and vaccines, crop protection and seed treatments, and industrial applications. Its products are often small components of the final product but critical to performance, which gives it pricing power and high margins in normal conditions.

The life sciences division, which supplies lipid systems for drug delivery, gained prominence during the Pandemic because of its role in mRNA vaccines. Since then, demand has normalised, and the company has been building a broader pharmaceutical pipeline.

The De-Stocking Hangover

After the pandemic, customers across consumer care and crop protection built up large inventories and then cut orders sharply to reduce stock. That de-stocking hit Croda's volumes and profits, leading to multiple profit warnings and a sharp fall in the share price. Volumes have since recovered in some areas, but the pace has been slower than hoped.

Why Croda Is a Value Stock

Croda International Plc (LSE:CRDA) is classed in this analysis as a large-cap value stock. Its shares have fallen far from their peak, and it trades at a lower multiple than its historic average. The company has a long record of Dividend growth and a strong balance sheet. Investors buying today are betting on a recovery to historic margins.

Cost Pressures

Higher energy and raw material costs linked to the Iran war affect chemical producers. Croda has been implementing cost savings and restructuring, including site consolidation, to protect margins. A strong dollar and euro movements also affect reported results.

Risks to Monitor

Key risks include a slower recovery in consumer care and crop protection, weak pharmaceutical demand, competition from lower-cost producers, energy cost Inflation and currency volatility. Any further downgrade would weigh on confidence.

Activist pressure has occasionally featured in speculation about Croda's strategy, including potential portfolio changes to unlock value.

Sector Context

European chemicals companies have broadly struggled in 2026 because of high energy costs and weak industrial demand. A peace deal that lowers energy prices could help the sector, while further escalation in the Middle East would add pressure.

What Investors Are Watching Next for Croda International Plc (LSE:CRDA)

Investors will watch peer results, energy prices, any trading update in early 2027 and full-year results in February. Evidence of sustained Volume recovery and Margin improvement is the key catalyst for Croda International Plc (LSE:CRDA) to re-rate as a FTSE 100 large-cap value stock.

Market Backdrop on 13 November 2026

The wider market backdrop matters for Croda International Plc (LSE:CRDA). The FTSE 100 closed on Friday, 13 November 2026, at 10,902.56, up 2.2% on the week and at its highest level in three months, while the FTSE 250 slipped 0.5% on the day. UK third-quarter GDP growth of 0.7%, the fastest pace in more than two years, has improved confidence in the domestic economy, even as the Bank of England's rise to 4% and US Treasury yields above 5.1% raise the bar for Equity valuations. European chemicals remain out of favour because of high energy costs and patchy industrial demand. For a large-cap value stock in the FTSE 100, that mix of resilient growth, higher rates and volatile Commodity and technology markets is likely to keep trading active into the end of the year.

Retail investor interest has also been strong. Discussion of Croda International Plc (LSE:CRDA) has picked up on investing forums and social platforms this week, with traders comparing valuations, dividend yields and upcoming catalysts across the FTSE 100 as they reposition portfolios before year-end.